CPG-7909 (PF-3512676, ProMune®):: toll-like receptor-9 agonist in cancer therapy

被引：47
|
作者：
Murad, Yanal M.
Clay, Timothy M.
Lyerly, H. Kim
Morse, Michael A.
机构：
[1] Duke Univ, Med Ctr, Program Mol Therapeut, Ctr Comprehens Canc,Dept Surg, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Program Mol Therapeut, Duke Comprehens Canc Ctr,Dept Pathol & Immunol, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Program Mol Therapeut, Comprehens Canc Ctr,Dept Med, Durham, NC 27710 USA
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2007年 / 7卷 / 08期
关键词：
adjuvant; CPG-7909; PF-3512676; ProMune; TLR9;
D O I：
10.1517/14712598.7.8.1257
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Stimulation of toll-like receptor (TLR)9 activates human plasmacytoid dendritic cells and B cells, and induces potent innate immune responses in preclinical tumor models and in patients. CpG oligodeoxynucleoticles (ODNs) are TLR9 agonists that show promising results as vaccine adjuvants and in the treatment of cancers, infections, asthma and allergy. PF-3512676 (ProMune((R))) was developed as a TLR9 agonist for the treatment of cancer as monotherapy and as an adjuvant in combination with chemo- and immunotherapy. Phase I and II trials have tested this drug in several hematopoietic and solid tumors. Pfizer has initiated Phase III trials to test PF-3512676 in combination with standard chemotherapy for non-small-cell lung cancer.
引用
收藏
页码：1257 / 1266
页数：10
相关论文
共 50 条
  • [31] Expression of Toll-Like Receptor-9 Is Increased in Poorly Differentiated Prostate Tumors
    Vaisanen, Marja-Riitta
    Vaisanen, Timo
    Jukkola-Vuorinen, Arja
    Vuopala, Katri S.
    Desmond, Renee
    Selander, Katri S.
    Vaarala, Markku H.
    PROSTATE, 2010, 70 (08): : 817 - 824
  • [32] Bacterial DNA delays neutrophil apoptosis via toll-like receptor-9
    Filep, JG
    Khreiss, T
    József, L
    JOURNAL OF LEUKOCYTE BIOLOGY, 2004, : 61 - 61
  • [33] Expression of Toll-like receptor-9 is associated with poor progression-free survival in prostate cancer
    Vaisanen, Marja-Riitta
    Jukkola-Vuorinen, Arja
    Vuopala, Katri S.
    Selander, Katri S.
    Vaarala, Markku H.
    ONCOLOGY LETTERS, 2013, 5 (05) : 1659 - 1663
  • [34] Toll-like receptor-9 in Spanish multiple sclerosis patients: an association with the gender
    Dominguez-Mozo, M. I.
    Garcia-Montojo, M.
    Lopez-Cavanillas, M.
    De Las Heras, V.
    Garcia-Martinez, A.
    Arias-Leal, A. M.
    Casanova, I.
    Urcelay, E.
    Arroyo, R.
    Alvarez-Lafuente, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 (03) : 537 - 540
  • [35] Toll-like Receptor-9 Agonist Reverses T Cell Exhaustion in a Murine Model of Pediatric B-ALL
    Atre, Tanmaya
    Reid, Gregor S. D.
    BLOOD, 2023, 142
  • [36] Toll-like receptor-9 expression induced by tape-stripping triggers on effective immune response with CpG-oligodeoxynucleotides
    Inoue, Joe
    Aramaki, Yukihiko
    VACCINE, 2007, 25 (06) : 1007 - 1013
  • [37] Toll-like receptor-9 induced by physical trauma mediates release of cytokines following exposure to CpG motif in mouse skin
    Liu, L
    Zhou, XH
    Shi, JY
    Xie, X
    Yuan, ZH
    IMMUNOLOGY, 2003, 110 (03) : 341 - 347
  • [38] Toll-like receptor 9 in breast cancer
    Sandholm, Jouko
    Selander, Katri S.
    FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [39] Toll-Like Receptor 9 Agonists in Cancer
    Karapetyan, Lilit
    Luke, Jason J.
    Davar, Diwakar
    ONCOTARGETS AND THERAPY, 2020, 13 : 10039 - 10060
  • [40] Toll-Like Receptor-2/6 and Toll-Like Receptor-9 Agonists Suppress Viral Replication but Not Airway Hyperreactivity in Guinea Pigs
    Drake, Matthew G.
    Evans, Scott E.
    Dickey, Burton F.
    Fryer, Allison D.
    Jacoby, David B.
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2013, 48 (06) : 790 - 796
12345